Remove Books Remove FDA Remove Labelling
article thumbnail

The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs

The FDA Law Blog

Karst The FDA Reduction-in-Force (Termination)or RIF(T)announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIFd. As folks steeped in the world of generic drugs And Hatch-Waxman know, theres a lot that happens before FDA can take action on an ANDA.

FDA 144
article thumbnail

Q&A: How gluten-free processed foods put people with celiac disease at risk

STAT

The story of how the food industry went gaga for gluten-free products, putting the health of people with celiac at risk in the process, takes center stage in Emily Abel’s new book, “Gluten Free for Life: Celiac Disease, Medical Recognition, and the Food Industry.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Understanding Recent Changes to 505(b)(2) Drugs and Reimbursement

Pharmacy Times

The Orange Book is the reference, and it allows the FDA to declare something [to be] therapeutically equivalent. The FDA Approval Process Within the FDA approval process, the 505(b)(1) new drug application (NDA) submission pathway is the pathway by which new drugs are able to seek approval.

FDA 65
article thumbnail

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

There are too many drug approvals, label updates, and new data published for even the most skilled and experienced oncology pharmacist to keep up with, let alone those still building their baseline knowledge. Touchstone Books; 2013. Oncology pharmacy practice changes at a rapid pace. Time Enough for Love. Putnam’s Sons; 1973.

article thumbnail

STAT+: Pharmalittle: We’re reading about the gray market for obesity meds, an RSV drug recommendation, and more

STAT

If the weather does not cooperate, there is always a good book or the telly. Shipments of such active ingredients from Chinese entities not registered with the FDA jumped by 44% in January from the previous month, according to the Partnership for Safe Medicines, an industry group. Enflonsia was approved by the FDA in early June.

article thumbnail

FDA whittles back Aduhelm approval amid concern over broad label

pharmaphorum

One of the criticisms levelled at the FDA over its approval of Biogen and Eisai’s Alzheimer’s disease drug Aduhelm was its decision to clear use of the drug in a broader group of patients than was included in clinical trials. ” The post FDA whittles back Aduhelm approval amid concern over broad label appeared first on. .”

article thumbnail

ViiV, J&J get FDA nod for simpler HIV injectable dosing

pharmaphorum

The FDA has given ViiV healthcare and Johnson & Johnson a boost in the market for long-acting injectable HIV drugs, approving a new regimen for their Cabenuva product that does away with the need for an oral lead-in period. The post ViiV, J&J get FDA nod for simpler HIV injectable dosing appeared first on.

FDA 98